Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW642444H · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GW642444M 25mcg | EXPERIMENTAL | Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning. |
| GW642444M 100mcg | EXPERIMENTAL | Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning. |
| GW642444M 400mcg | EXPERIMENTAL | Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning. |
| GW642444H 100mcg | EXPERIMENTAL | Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning. |
| placebo | PLACEBO_COMPARATOR | Subject will inhale single dose of Placebo via a DISKUS device in morning. |
| Name | Type | Description |
|---|---|---|
| GW642444H (100mcg) | DRUG | H salt |
| placebo | DRUG | placebo |
| GW642444M (25, 100 & 400 mcg) | DRUG | M salt |
Inclusion criteria: * male or female (of non-childbearing potential) between 18 - 70 years * History of stable mild to moderate asthma * non - smokers * currently taking daily doses of inhaled fluticasone propionate 200 - 500 mcg (or equivalent) * body weight \>50 kg with BMI 19-29.9 kg/m2 * normal...
GW642444H is an investigational small molecule drug developed by GSK plc for Pulmonary Disease, Chronic Obstructive, a respiratory condition. It has been studied in a single Phase 1 clinical trial and is not approved for any use. The compound is also referred to as GW642444H (100mcg), reflecting the 100 microgram dose evaluated in testing.
GW642444H has been studied for Pulmonary Disease, Chronic Obstructive, commonly known as COPD. The only registered trial involving this drug was conducted in patients with that condition. It remains an investigational agent and is not approved for the treatment of COPD or any other indication.
GW642444H is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 1 study of the compound. No other developer or partner is associated with this asset based on the available information.
GW642444H is in Phase 1 clinical development. It has completed one Phase 1 trial and has no active trials at this time. The drug is investigational and has not received FDA approval for any indication.
GW642444H has been evaluated in one completed Phase 1 trial, NCT00463697, titled a study to investigate the effect of inhaling a single dose of GW642444M in asthmatic patients. The trial enrolled 20 participants in the United Kingdom and was randomized, double-blind, and placebo-controlled.